Menu

Blog

Page 2316

Oct 28, 2023

This Portable Innovation Saves Lives by Bringing Doctors to 30 Lakh Pregnant Women

Posted by in categories: biotech/medical, innovation

“High-risk mothers in many parts of rural India are usually identified in the third trimester, which is around the eighth month of pregnancy. However, by this time, it’s often too late to manage complications before labour. This can lead to fatal outcomes,” says Senthil Kumar Murugesan.

An electronics and communications engineer by profession, Senthil is trying to bridge this gap with JioVio Healthcare, an IoT-based maternal healthcare startup that provides early-risk monitoring services at home.

He first encountered the pregnancy healthcare gap when his sister was pregnant in 2016. She is a career-driven woman and would miss her antenatal appointments due to the lack of time. Also, the… More.

Continue reading “This Portable Innovation Saves Lives by Bringing Doctors to 30 Lakh Pregnant Women” »

Oct 28, 2023

The Importance of MSI Status

Posted by in category: satellites

High Microsatellite Instability is an emerging biomarker for immune-oncology that can be predictive of positive response to immunotherapy.


Tumors with defects in the expression of functional MMR (dMMR) proteins often have somatic mutations that produce novel or “foreign” proteins. These proteins can be immunogenic. As a result, these tumors are effective at priming an immune response and subsequently susceptible to immunotherapies. Because MSI can be the first evidence of an MMR deficiency, MSI-H status is predicative of a positive response to immunotherapies such as immune checkpoint blockade inhibitors.

Oct 28, 2023

AI Can Screen for Diabetes

Posted by in categories: biotech/medical, food, health, mobile phones, robotics/AI, sex, time travel

In America, roughly 40 million Americans have diabetes and about 95% of them have type 2 diabetes. Type 2 diabetes occurs when the body cannot correctly process sugar and fuel cells. More specifically, the body does not produce enough insulin to break down sugar into glucose for the cells to use. In this case, treatment includes insulin shots or a pump in addition to a strict diet excluding sweets or high fat meals. Treatment limitations disrupt patient quality of life. Some researchers have been working on better detection for diabetic retinopathy with artificial intelligence (AI), but research is limited on how to better detect diabetes itself. Thus, many researchers are working to detect diabetes early on and discover better treatments.

Klick labs, located in multiple cities across the world, is trying to detect type 2 diabetes by having a patient speak into a microphone for 10 seconds. Klick labs believes this technology can better detect diabetes and help patients get treatment earlier. The study was published in Mayo Clinic Proceedings: Digital Health, which details how patients spoke for 10 seconds and combined with health data, including age, sex, height, and weight, created an AI model that discerns whether a person has type 2 diabetes or not. After further tests, scientists determined it has 89% and 86% accuracy for women and men, respectively.

In the study, Klick Labs collected voice recordings of 267 people, either non-diabetic or diabetic. The participants were asked to record a phrase into their smartphones six times a day for a total of 2-weeks. Over 18,000 recordings were taken and analyzed to distinguish 14 acoustic features that helped distinguish non-diabetic to type 2 diabetic individuals. The research highlights specific vocal variations in pitch and intensity that could lead to how the medical community screens for early-onset diabetes. A major barrier to early detection includes time, travel, and cost, which many people do not have. Voice diagnosis can help eliminate those barriers and improve detection and treatment in diabetic patients.

Oct 28, 2023

Rice-Sized Device Tests Brain Tumor’s Drug Responses During Surgery

Posted by in categories: biotech/medical, neuroscience

Scientists have made remarkable progress in understanding the underlying changes that make cancer grow and have applied this knowledge to develop and guide targeted treatment approaches to vastly improve outcomes for people with many cancer types. And yet treatment progress for people with brain tumors known as gliomas—including the most aggressive glioblastomas—has remained slow. One reason is that doctors lack tests that reliably predict which among many therapeutic options will work best for a given tumor.

Now an NIH-funded team has developed a miniature device with the potential to change this for the approximately 25,000 people diagnosed with brain cancers in the U.S. each year [1]. When implanted into cancerous brain tissue during surgery, the rice-sized drug-releasing device can simultaneously conduct experiments to measure a tumor’s response to more than a dozen drugs or drug combinations. What’s more, a small clinical trial reported in Science Translational Medicine offers the first evidence in people with gliomas that these devices can safely offer unprecedented insight into tumor-specific drug responses [2].

These latest findings come from a Brigham and Women’s Hospital, Boston, team led by Pierpaolo Peruzzi and Oliver Jonas. They recognized that drug-screening studies conducted in cells or tissue samples in the lab too often failed to match what happens in people with gliomas undergoing cancer treatment. Wide variation within individual brain tumors also makes it hard to predict a tumor’s likely response to various treatment options.

Oct 27, 2023

China’s BlackTech Hacking Group Exploited Routers to Target U.S. and Japanese Companies

Posted by in categories: cybercrime/malcode, government

How safe are our routers? Japan & U.S. cybersecurity agencies have flagged a major threat in the form of China’s BlackTech group.

Learn more about the threat:


BlackTech, a notorious state-backed hackers from China, are using router backdoors to quietly to breach government, tech, and media sectors in the U.S.

Oct 27, 2023

Five Protons Spew Out of Extreme Nucleus

Posted by in categories: particle physics, space

A highly unstable nucleus that decays by emitting five protons has been observed, offering an extreme case for testing nuclear models.

Researchers have found evidence of an extremely unstable nucleus for which more than half of the component particles are unbound, meaning that they are not tightly connected to the dense core of the nucleus [1]. The nucleus, nitrogen-9, is composed of a small helium-like core surrounded by five untethered protons that quickly escape after the nucleus’s formation. Previous experiments have seen at most four unbound protons in a nucleus. The research team had to carefully sift through a large volume of nuclear-collision data to identify the nitrogen-9 decays. This barely bound nucleus poses a unique challenge to theories of nuclear structure.

A nucleus with a large imbalance between its numbers of protons and neutrons is less stable than one in which the numbers are similar. In the extreme cases, these proton-or neutron-rich isotopes are unbound, meaning that one or more nucleons escape during decay. The boundaries between bound and unbound states—both on the proton-rich and on the neutron-rich sides of the nuclear landscape—are called drip lines. Researchers are interested in finding nuclei beyond the drip lines because they offer tests of models at the limits of nuclear existence. These exotic nuclei may also play a role in the formation of heavy elements in supernovae and in neutron star mergers.

Oct 27, 2023

Strong Light–Matter Coupling in the Simplest Geometry

Posted by in category: nanotechnology

A single-layer transition-metal dichalcogenide on top of a silver film displays strong light–matter coupling without the need for nanostructures or microcavities.

Oct 27, 2023

Simply Being Told You Were Given Ketamine Could Be Enough to Treat Depression

Posted by in categories: biotech/medical, neuroscience

For those with stubbornly resistant forms of severe depression, ketamine was looking more and more like a solution. Years of research has hinted at the dissociative anesthetic’s treatment potential where other medications failed, promising the benefits of electroshock therapy with far fewer risks.

For all of the excitement, separating the hope from the hype has been challenged by the drug’s strong psychoactive effects. How can you conduct a blind test for a drug that so overtly detaches the mind from the body?

By taking advantage of the unconscious state of patients under general anesthesia, researchers from Stanford University School of Medicine in the US put ketamine to the ultimate, gold standard test.

Oct 27, 2023

350-Year-Old Theorem Reveals ‘Profound’ Connection Between Properties of Light

Posted by in category: physics

Dutch-born Christiaan Huygens is probably one of the most famous physicists you’ve never heard of. His work in the late 17th century straddled both the intangible and tangible realms of our Universe: the nature of light, and the mechanics of moving objects.

Among his many contributions, Huygens proposed a wave theory of light that would give rise to physical optics, which deals with the interference, diffraction, and polarization of light. He also invented the first pendulum clock; the most accurate timekeeper for almost 300 years, right through the Industrial Revolution.

Little has been made of the connections between these two seemingly disparate fields of optics and classical mechanics – until now.

Oct 27, 2023

Exclusive: Ilya Sutskever, OpenAI’s chief scientist, on his hopes and fears for the future of AI

Posted by in categories: futurism, robotics/AI

OpenAI’s CEO, Sam Altman, spent a good part of the summer on a weeks-long outreach tour, glad-handing politicians and speaking to packed auditoriums around the world. But Sutskever is much less of a public figure, and he doesn’t give a lot of interviews.

He is deliberate and methodical when he talks. There are long pauses when he thinks about what he wants to say and how to say it, turning questions over like puzzles he needs to solve. He does not seem interested in talking about himself. “I lead a very simple life,” he says. “I go to work; then I go home. I don’t do much else. There are a lot of social activities one could engage in, lots of events one could go to. Which I don’t.”

But when we talk about AI, and the epochal risks and rewards he sees down the line, vistas open up: “It’s going to be monumental, earth-shattering. There will be a before and an after.”